A Phase I/II Study of ABI-007 (Abraxane®, Nab®-Paclitaxel)and Vinorelbine in Patients With Stage IV (Metastatic) Breast Cancer
NCT00140140
Terminated
The purpose of this study is to: 1) determine the optimal tolerated dose of ABI-007 and vinorelbine, given concurrently on a weekly basis, in the absence of planned growth factor support with granulocyte colony-stimulating factor (G-CSF) (Patients with HER-2/neu positive disease may receive Herceptin, and 2) determine the optimal tolerated dose of ABI-007 and vinorelbine, given concurrently on a weekly basis, in the presence of planned growth factor support with G-CSF.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/22/2019
Locations: City of Hope Comprehensive Cancer Care Center, Duarte, California +1 locations
Conditions: Stage IV (Metastatic) Breast Cancer
Register for Updates
TARCEVA (Erlotinib) in Combination With Chemoradiation in Patients With Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC)
NCT00563784
Completed
The goal of this clinical research study is to find out if erlotinib given with chemotherapy and radiation therapy can help to control NSCLC. The safety of this combination treatment will also be studied. Researchers will also test the tissue from your earlier biopsy to measure the levels of epidermal growth factor receptor (EGFR). The purpose of EGFR testing is to learn about any link between various forms of EGFR and your response to treatment with erlotinib.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/18/2019
Locations: University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Non-Small Cell Lung Cancer, Lung Cancer
Register for Updates
A Safety Study of ABI-007 for In-Stent Restenosis
NCT00093223
Completed
This trial will treat patients with a new chemotherapeutic medicine who have undergone a successful and uncomplicated de novo stent placement in up to two native coronary arteries. The purpose of the trial is to determine the appropriate dose of the new medicine for future trials and to evaluate the incidence of treatment-emergent adverse events and serious adverse events.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/14/2019
Locations: Abraxis BioScience, Inc., Durham, North Carolina
Conditions: Angina Pectoris, Coronary Artery Disease
Register for Updates
Use of ABI-007 for the Prevention of Vascular Access Graft Failure in Patients Undergoing Hemodialysis
NCT00249002
Terminated
This study is designed to confirm the safety of the proposed dose and schedule of ABI-007 for hemodialysis patients with vascular access device failure, and to obtain preliminary data on the effectiveness of such treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/14/2019
Locations: Not set, Peoria, Illinois +3 locations
Conditions: Hemodialysis Graft Dysfunction
Register for Updates
Study of Albumin-bound Paclitaxel (Abraxane) in Combination With Carboplatin and Herceptin in Patients With Advanced Breast Cancer
NCT00093145
Completed
This trial will treat patients with advanced breast cancer with a new anti-cancer medicine used in combination with two existing anti-cancer medications: Albumin-bound paclitaxel (ABI-007), Carboplatin and Herceptin. Participants will be given the combination therapy on a weekly basis and may continue on therapy as long as their condition improves and drug toxicity is tolerated.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
11/13/2019
Locations: Breastlink Med Group, Long Beach, California +13 locations
Conditions: Breast Cancer
Register for Updates
ABI-007 In Combination With Bevacizumab in Women With Metastatic Breast Cancer
NCT00394082
Completed
The purpose of this study is to evaluate the safety and tolerability of weekly ABI-007 in combination with bevacizumab. The evaluation of progression-free survival of weekly ABI-007 in combination with bevacizumab for patients with previously untreated advanced/metastatic breast cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
11/13/2019
Locations: Not set, Melbourne, Florida +19 locations
Conditions: Metastatic Breast Cancer
Register for Updates
The OPC for Optimal Delivery of Paclitaxel for the Prevention of Endovascular Restenosis - Above and Below the Knee
NCT02464501
Completed
The purpose of this study is to assess the safety and efficacy of paclitaxel administration using the occlusion perfusion catheter (OPC) for the prevention of restenosis in infrainguinal de novo, restenotic femoropopliteal and infrapopliteal stenoses and occlusions, and in-stent restenosis.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/07/2019
Locations: Cardiology Associates, Fairhope, Alabama +16 locations
Conditions: Peripheral Arterial Disease, Cardiovascular Disease, Peripheral Vascular Disease
Register for Updates
Weekly vs. Every 2 Week vs. Every 3 Week Administration of ABI-007 (Abraxane)/Bevacizumab Combination in Metastatic Breast Cancer
NCT00281528
Terminated
This is a multi-center, open-label, randomized Phase II study in previously untreated patients with metastatic breast cancer to evaluate the antitumor activity and safety of weekly dose-dense ABI-007 (Abraxane) compared to 2-weekly regimen vs the standard 3-weekly infusion. All patients will also receive concurrent bevacizumab.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
11/07/2019
Locations: Division of Hematology/Oncology University of Alabama at Birmingham, Birmingham, Alabama +39 locations
Conditions: Breast Neoplasms, Neoplasm Metastasis
Register for Updates
Study of Dose-dense Adriamycin Plus Cytoxan (AC) Followed by Either ABI-007 (Abraxane) or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast Cancer
NCT00394251
Completed
The primary objective of this study was to compare the safety of dose-dense ABI-007 (Abraxane) 260 mg/m\^2 or Taxol 175 mg/m\^2 given every 2 weeks following dose-dense Adriamycin plus Cytoxan (AC) chemotherapy. Bevacizumab was administered at 10 mg/kg every 2 weeks throughout chemotherapy, and then at 15 mg/kg every 3 weeks following chemotherapy.
Gender:
FEMALE
Ages:
Between 18 years and 70 years
Trial Updated:
11/07/2019
Locations: Not set, Birmingham, Alabama +26 locations
Conditions: Breast Cancer
Register for Updates
Gemcitabine Plus Albumin-bound Paclitaxel In Patients With Advanced Metastatic Pancreatic Cancer
NCT00398086
Completed
To determine the maximum tolerated dose and dose-limiting toxicity of Gemcitabine plus Albumin-bound paclitaxel (ABI-007) in patients with advanced metastatic pancreatic cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/07/2019
Locations: University of Alabama at Birmingham Comprehensive Cancer Ctr, Birmingham, Alabama +4 locations
Conditions: Metastatic Pancreatic Cancer
Register for Updates
A Phase 1b Study of Paclitaxel And Ricolinostat For The Treatment Of Gynecological Cancer
NCT02661815
Terminated
Participants with Ovarian, Fallopian Tube, or Peritoneal Cancer that has recurred within 12 months of prior treatment that includes Platinum Chemotherapy are invited to take part in this study. This research study is studying a combination of a new chemotherapy drug called Ricolinostat together with the chemotherapy Paclitaxel and a drug called Bevacizumab as a possible treatment for this diagnosis.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
11/07/2019
Locations: Massacusetts General Hospital, Boston, Massachusetts +1 locations
Conditions: Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
Register for Updates
Phase III Study of ABI-007(Albumin-bound Paclitaxel) Plus Gemcitabine Versus Gemcitabine in Metastatic Adenocarcinoma of the Pancreas
NCT00844649
Completed
Phase III Metastatic Pancreatic Cancer
Gender:
ALL
Ages:
Between 18 years and 79 years
Trial Updated:
11/07/2019
Locations: UAB Comprenhensive Cancer Center at University of Alabama, Birmingham, Alabama +192 locations
Conditions: Metastatic Pancreatic Cancer
Register for Updates